Authors
Latest:
Perspectives on intravenous bevacizumab repackaged for intravitreal useAlthough off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
Latest:
Impact of Durable Therapies on Patients and Clinics and Monitoring StrategiesPanelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.
Latest:
Prevent Blindness implements Diabetes + the Eyes Advisory Committee to combat diabetes-related eye diseasesThe committee will work to help the organization increase awareness and early identification of diabetes-related eye diseases and improve access to eye care treatment, policy development, research, and surveillance.
Latest:
EURETINA Innovation Spotlight kickstarts the 2025 CongressAnat Loewenstein, MD, president of EURETINA, announces the EURETINA Innovation Spotlight (EIS) will return on September 3 this year.
Latest:
Impressions and take away points from Patient Case #2A retina specialist discusses impressions and key take away points from patient case.
Latest:
Reducing site burden and expanding research capacity with AIHow artificial intelligence could enhance clinical trials.
Latest:
Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMODr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Latest:
How I use MicroPulse Laser to treat DMEDr. Jorge Calzada shares his methods for treating diabetic macular edema with MicroPulse Laser and anti-VEGF injections.
Latest:
Key Takeaways on Managing Neovascular AMD and DMENathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.
Latest:
Training and practice are key to learning retinal injection techniquesIn-person and virtual trainings, coupled with the support of local product representatives, are the best ways to ensure retina specialists are set up for success.
Latest:
Managing retinal folds, role of anterior vitreous in retinal detachmentsGrazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.
Latest:
Comparing vorolanib intravitreal insert with aflibercept in DME treatmentEYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.
Latest:
Transforming preinjection protocolsThe role of compounded anesthetic formulations in streamlining efficiency and elevating patient care.
Latest:
Snowmass Retina & Eye 2025: Ronald Frenkel, MD, previews the unique agenda with a fusion of retina, cataract, and glaucomaThe 15th annual meeting, taking from March 24–28 in Snowmass, Colorado, will deliver high-impact discussions on macular disease, artificial intelligence in ophthalmology, and breakthrough therapies—plus opportunities for networking on and off the slopes.
Latest:
Early intervention helps with vision protection in macular degenerationRetina specialist Priya Vakharia, MD, reveals promising ANX007 trial results, showing potential to prevent vision loss in geographic atrophy.
Latest:
What is encapsulated cell therapy?John Pollack, MD, discusses gene therapy advancements in the first installment of his blog for Modern Retina.
Latest:
True-to-life retinal imaging with the new ultra-widefield color RGB modalityDigital exclusive article on red-blue-green ultrawidefield (UWF) imaging
Latest:
EMA grants Orphan designations to MCO-010, FDA grants RMAT in Stargardt diseaseMCO-010 receives Orphan and RMAT designations, highlighting its potential as a groundbreaking therapy for various retinal dystrophies.
Latest:
Two Faricimab Patient Cases from the Real-world in Neovascular AMDDr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.
Latest:
A field guide to optic disc drusenClinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.
Latest:
Making the case for nurses to inject dexamethasone implantsSafety data on non-clinician-led services have shown a low complication rate
Latest:
The significance of imaging and treatment in lattice retinal degenerationPrompt evaluation and adherence to guidelines for treatment recommendations for lattice retinal degeneration are essential to the preservation of vision and sight.
Latest:
Gene therapy: Where the action is for retinal diseasesFoundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.
Latest:
Q&A: Sally S. Ong, MD on the neighborhood-level characteristics associated with delay in surgery and loss to follow-upResearch reveals how neighborhood social factors impact patients with tractional retinal detachments, highlighting the need for improved access to care and support.
